

## Title Page

**Manuscript Title:** Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis

### Authors:

Jasmin Elkin, BBiomed(Hons)<sup>1</sup>

Siddharth Rele, BBiomedSc, MD, PhD, GDipSurgAnat<sup>1</sup>

Priya Sumithran, MBBS, PhD<sup>3,4</sup>

Michael Hii, MBBS, BMedSci, PGDipSurgAnat, FRACS<sup>1</sup>

Sharmala Thuraisingam, PhD, MBiostat, BEMech(Hons)<sup>1</sup>

Tim Spelman, PhD, MBBS, BSc<sup>1</sup>

Tuong Phan, MBBS, DMedSci, PGDipClinUS, PGDipBiostat, FANZCA<sup>2</sup>

Peter Choong, MBBS, MD, FRACS, FAOrthA, FAAHM<sup>1</sup>

Michelle Dowsey, BHealthSci(Nursing), MEpi, PhD<sup>1</sup>

Cade Shadbolt, MA<sup>1</sup>

### Author affiliations:

<sup>1</sup>Department of Surgery, The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

<sup>2</sup>Department of Critical Care, The University of Melbourne, St Vincent's Hospital Melbourne, Anaesthesia and Acute Pain Medicine, Fitzroy, Australia

<sup>3</sup> Department of Surgery, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

<sup>4</sup> Department of Endocrinology and Diabetes, Alfred Health, Melbourne, VIC 3004, Australia

**None.** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Corresponding author:**

Cade Shadbolt

Department of Surgery, St Vincent's Hospital, Level 2, Clinical Sciences Building, 29

Regent Street, Fitzroy, Victoria 3065

[cade.shadbolt@unimelb.edu.au](mailto:cade.shadbolt@unimelb.edu.au)

**Manuscript word count: 2,972**

## Key Points

**Question:** What is the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and the risk of pulmonary aspiration or residual gastric contents in fasted patients undergoing anesthesia?

**Findings:** This systematic review and meta-analysis of 25 observational studies involving 464,552 patients found that preoperative GLP-1 RA exposure was not associated with pulmonary aspiration among patients undergoing surgery despite being associated with an elevated risk of residual gastric contents.

**Meaning:** Currently there is limited evidence to suggest that patients using GLP-1 RAs are at a heightened risk of pulmonary aspiration, despite presenting more often to surgery with residual gastric contents than those not using GLP-1 RAs.

## Abstract

**Importance:** Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to slow gastric emptying, however the association between GLP-1 RA use and perioperative aspiration risk is not known.

**Objective** To summarize the evidence on whether GLP-1 RA exposure is associated with (1) pulmonary aspiration in patients undergoing procedures requiring anesthesia or sedation, or (2) increased residual gastric contents among fasted patients.

**Data Sources** MEDLINE, EMBASE, Web of Science, and Cochrane Central ClinicalTrials.gov and WHO ICTRP registries (updated 21 Oct 2024), and citation tracking of included studies (25 Oct 2024).

**Study Selection:** Studies assessing perioperative pulmonary aspiration or residual gastric contents among fasted patients who were using any form of GLP-1 RA.

**Data extraction and synthesis:** Data was extracted independently and in duplicate. Pooled odds ratios (ORs) were estimated for each outcome using random effect meta-analysis. Certainty of the evidence for each outcome was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.

**Main outcomes measures:** Pulmonary aspiration and increased residual gastric contents, a common surrogate for aspiration risk.

**Results:** Of 7,994 screened studies, 25 observational studies were included in the analysis. In a meta-analysis of 9 studies involving 184,724 individuals and 471 cases of aspiration, GLP-1RA exposure was not associated with pulmonary aspiration (OR, 1.04; 95% CI, 0.87-1.25, low certainty evidence). In a meta-analysis of 16 studies involving 164,330 individuals and 3,742 cases of residual gastric contents, GLP-1RA exposure was positively associated with residual gastric contents despite appropriate fasting (OR, 4.57;

95% CI, 3.30-6.33, very low certainty evidence). In a meta-analysis of 2 studies involving 877 individuals and 105 cases of residual gastric contents, withholding at least one dose of GLP-1 RA prior to a procedure was not associated with a lower odds of residual gastric contents (OR, 0.67; 95% CI, 0.12-3.67, very low certainty evidence).

**Conclusion:** Patients using GLP-1RAs are at heightened risk of presenting to surgery with residual gastric contents, though the available evidence does not indicate that this translates to an elevated risk of aspiration. Further research is needed to evaluate the risks and benefits of different strategies for managing these medications during the perioperative period.

## Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for management of obesity and type 2 diabetes.<sup>1</sup> GLP-1 RAs are known to slow the rate of postprandial gastric emptying,<sup>2-4</sup> and there have been recent anecdotal accounts of patients who are taking these medications before surgery aspirating or having increased residual gastric contents despite appropriate fasting.<sup>5-14</sup> This has led various professional organizations to acknowledge that patients taking these medications may be at a heightened risk of pulmonary aspiration or regurgitation during the perioperative period.<sup>15-17</sup>

Guidance from the American Society of Anesthesiologists (ASA) released in 2023 recommends withholding one dose of GLP-1 RA prior to a procedure.<sup>16</sup> Other professional bodies have refrained from recommending to withhold these medications before surgery, citing limitations in the available data.<sup>18-20</sup> Previous systematic reviews have examined the risk of aspiration or residual gastric contents among GLP-1 RA users, however they have been limited to patients undergoing endoscopic procedures,<sup>21, 22</sup> or those temporarily exposed to GLP-1 RAs during the perioperative period.<sup>23</sup> To address uncertainty, this systematic review aimed to summarize the available evidence on whether GLP-1 RA exposure is associated with: (1) pulmonary aspiration in patients undergoing procedures requiring anesthesia or sedation, or (2) increased residual gastric contents among fasted patients. This review also aimed to synthesize the evidence on whether withholding GLP-1 RA medications is associated with reductions in the risk of perioperative aspiration or the presence of residual gastric contents in fasted patients.

## Methods

We conducted a systematic review and meta-analysis in line with our prespecified protocol (PROSPERO: CRD42024532229) and reported according to the Preferred

Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement<sup>24</sup> and Meta-analyses Of Observational Studies in Epidemiology (MOOSE) reporting guidelines.<sup>25</sup> Deviations and clarifications to the initial protocol are presented in the supplement (eTable 1 in the Supplement). During the review process, discordance between reviewers were resolved through discussion, or via adjudication by an additional reviewer if consensus could not initially be achieved.

### **Search strategy**

We searched MEDLINE, EMBASE, Web of Science, and Cochrane Central on 19 March 2024 and completed an updated search on 21 Oct 2024 (eMethods 1 in the Supplement). The search was limited to studies published from 2005 onwards, as this was the year of the first approval of a GLP1-RA by the Food and Drug Administration. The ClinicalTrials.gov and WHO ICTRP registries were searched on the same date for information on unpublished or ongoing studies. Forward and backwards citation tracking of included studies was last updated on 25 Oct 2024 using an automated online platform that has been described previously.<sup>26</sup>

### **Selection criteria**

Randomized controlled trials and observational studies were eligible for inclusion if they reported on the association between preoperative GLP-1 RA use and risk of: (1) pulmonary aspiration in fasted patients undergoing anesthesia or procedural sedation; or (2) residual gastric contents in fasted patients undergoing procedures requiring anesthesia or procedural sedation or in healthy volunteers that had fasted for at least 6 hours from solid foods and at least 2 hours for clear liquids, in accordance with standard preoperative fasting requirements.<sup>27</sup>

Studies were excluded if fasting duration was not reported, except for studies involving elective procedures where fasting was assumed to be a requirement. We also excluded studies where the GLP1-RA was commenced in the immediate perioperative period (i.e., within 14 days prior to the procedure or outcome measurement). Non-English studies and conference abstracts were not eligible for inclusion. When multiple studies were derived from the same sample, each study was included in the narrative summary though only the study with the lowest risk of bias across all 6 domains was included in pooled estimates. Ongoing or completed study without published results were identified during screening, but not included in the quantitative synthesis. Studies were screened independently and in duplicate (by JE and SR) using the Covidence systematic review software.<sup>28</sup> Reasons for excluded studies were reported and study authors were contacted to provide further information if eligibility was unclear.

### **Outcome measures**

Pulmonary aspiration included both direct measures of perioperative aspiration or postoperative respiratory complications that were directly attributed to aspiration (e.g. aspiration pneumonitis). Other respiratory complications that were not specifically attributed to perioperative aspiration did not meet this outcome definition. Residual gastric content included gastric residue identified via direct visualization during endoscopy of the upper gastrointestinal tract or gastric contents identified via ultrasound. Individual outcome definitions as described by the study authors are presented in the supplement (eTable 2-3 in the Supplement).

### **Data extraction and preparation**

Key study characteristics and outcome data were extracted from each of the included studies, independently and in duplicate (by CS and JE) using a structured data extraction



template. Adjusted odds ratios (OR) were the preferred effect estimates included in the meta-analyses of both outcomes. For estimates relating to aspiration, adjusted measures of relative risk (RR) were treated as adjusted ORs as odds approximates risk for low event rates.<sup>29</sup> When adjusted estimates were not reported, unadjusted ORs were calculated from the reported number of aspiration events in patients with and without GLP-1 RA exposure. For studies with no events in at least one arm, we added a continuity correction value to both arms that was inversely proportional to the sample size of the other study arm.<sup>29, 30</sup> For estimates relating to residual gastric contents, adjusted RRs were not treated as analogous to ORs, as this is a more common outcome. Study authors were contacted to provide adjusted ORs if multivariable analyses were reported alongside other measures of effect (eTable 4 in the Supplement), or these were estimated by the review team when study data were publicly available (eMethods 2 in the Supplement). When adjusted ORs could not be obtained, unadjusted ORs were calculated directly from the reported number of patients with residual gastric contents in exposed and unexposed groups.

### **Risk of bias**

Risk of bias assessment was conducted independently and in duplicate (by CS and JE) for each effect estimate rather than once per study.<sup>31</sup> For studies examining the association between preoperative GLP-1 RA exposure as compared to no exposure and the risk of pulmonary aspiration or residual gastric contents, we used a modified Quality in Prognosis Studies (QUIPS) tool.<sup>32,33</sup> For estimates of the association between withholding at least one dose of their GLP-1 RA and the study outcomes, we used the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool. In line with ROBINS-I recommendations, studies judged to be at critical risk of bias were excluded

from the meta-analyses.<sup>34</sup> For each of the included studies, bias due to confounding was evaluated by consideration of adjustment for important variables, including age, sex, body mass index (BMI), diabetes, ASA-physical status classification system, medications associated with delaying gastric emptying, and comorbidity burden.

### **Statistical analysis**

Effect estimates for pulmonary aspiration and residual gastric contents were pooled separately. Pooled odds ratios and 95% confidence intervals were calculated via random effect meta-analysis using the restricted maximum likelihood (REML) heterogeneity variance estimator.<sup>35,36</sup> Heterogeneity was assessed by estimating the  $I^2$  statistic. Funnel plots were assessed visually for evidence of small study bias, and the robustness of estimates to worst case publication bias was assessed by conducting meta-analyses including only non-affirmative studies.<sup>37</sup> Overall certainty of the evidence for each pooled estimate was evaluated in line with the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) non-contextualised approach, which accounts for risk of bias, inconsistency, indirectness, imprecision, and publication bias of the included studies not considering the clinical context.<sup>38</sup> All statistical analyses were performed using the *meta*, *metafor*, and *PublicationBias* packages in R Statistical Software (Version 4.3.2, R Core Team).<sup>39,40</sup>

## **Results**

### **Study Selection and Characteristics**

The literature search identified 7,994 study records (Figure 1), from which 25 observational studies involving 464,552 participants were included in the meta-analysis (Table 1). Fourteen studies that were ongoing or completed without published results at

the time of the final search are summarized separately in the online supplement (eTable 5 in the Supplement).

### **Pulmonary Aspiration**

Eleven retrospective studies assessed pulmonary aspiration among 335,186 patients (Table 2). Of these studies, 6 (55%) included patients who underwent esophagogastroduodenoscopy (EGD), 1 (9%) included EGD and/or colonoscopies, 1 (9%) included mixed endoscopic procedures, 1 (9%) included total knee arthroplasty (TKA), and 2 (18%) involved other elective surgeries. Instances of pulmonary aspiration were identified from electronic medical records or administrative claims data (eTable 2 of the Supplement). Three studies examined individuals undergoing similar procedures from the same administrative database. To avoid double counting of individuals,<sup>41</sup> the study with the lowest risk of bias across all 6 domains was included in the meta-analysis. Nine studies were included in the meta-analysis (Figure 2a). These studies examined 184,724 individuals, of which 471 cases of pulmonary aspiration were identified (Table 3). Preoperative exposure to GLP-1 RAs was not associated with pulmonary aspiration (OR, 1.04; 95% CI, 0.87-1.25,  $I^2=0\%$ ) (Figure 2a). Evaluation of indirectness suggested potential concerns due to a large proportion of studies restricted to endoscopic procedures or patients with diabetes (Table 3). Visual inspection of funnel plot asymmetry did not indicate small study effects (eFigure 1 in the Supplement). Sensitivity analysis restricted to non-affirmative studies was not performed due to an absence of affirmative studies. Overall risk of bias was moderate to high (eTable 6 in the Supplement). For most studies, bias was largely attributed to concerns with selection bias or incomplete adjustment for important prespecified confounders (eTable 7 in the Supplement). Overall certainty in the evidence was low (Table 3).

## **Residual Gastric Contents**

Seventeen studies assessed residual contents (Table 2). Of these studies, 12 (71%) included patients who had undergone an EGD procedure, 2 (12%) included EGD and/or colonoscopies, 1 (6%) included other elective surgeries, and 2 (12%) included healthy volunteers. Residual gastric contents were identified via retrospective review of electronic medical records for all 14 studies involving endoscopic procedures, with the remaining 3 studies having measured residual gastric content prospectively using gastric ultrasound (eTable 3 in the Supplement).

Sixteen studies were included in the meta-analysis (Figure 2b). These studies examined 164,330 individuals, of which 3,742 had residual gastric contents (Table 3). Preoperative GLP-1 RA exposure was associated with higher odds of residual gastric contents (OR, 4.57; 95% CI, 3.30-6.33;  $I^2=60%$ ) (Figure 2b), however this estimate was impacted by moderate to substantial heterogeneity. Although our certainty in evidence was increased due to the large effect, evaluation of indirectness suggested potential concerns due to a large proportion of studies restricted to endoscopic procedures (Table 3). Visual inspection of funnel plot asymmetry indicated that small study effects may have inflated this estimate (eFigure 2 in the Supplement), though a sensitivity analysis restricted to non-affirmative studies indicated that our pooled estimate was robust to even worse-case publication bias (OR, 3.29; 95% CI, 1.36-7.95) (eFigure 3-4 in the Supplement). Overall risk of bias was predominantly high (eTable 8 in the Supplement). For most studies, bias was largely attributed to high concerns with study participation, outcome measurement, and incomplete adjustment for important prespecified confounders (eTable 9 in the Supplement). Overall certainty in the evidence was very low (Table 3).

## **Association Between Time Since Last Dose and Residual Gastric Contents**

Three observational studies assessed the association between the time since last dose of GLP-1RA medication and residual gastric contents (Table 2). These studies examined 910 patients who were using GLP-1 RA, of whom 113 had residual gastric contents (eTable 10 in the Supplement). One of these studies examined a cohort using either weekly and daily dosed formulations, and the remaining studies were restricted to cohorts using weekly formulations. One study at critical risk of bias was excluded from the meta-analysis (eTable 11 in the Supplement).

Two studies were included in the meta-analysis (Figure 2c). These studies examined 877 individuals and 105 cases of residual gastric contents (Table 3). Withholding at least one dose of GLP-1 RA prior to a procedure was not associated with a lower odds of residual gastric contents (OR, 0.67; 95% CI, 0.12-3.67;  $I^2=66\%$ ). This estimate was impacted by substantial heterogeneity and very wide confidence intervals highlighting imprecision in this estimate (Table 3). Evaluation of indirectness suggested potential concerns due to a limited number of studies and half restricted to EGD procedures. Publication bias was not formally evaluated, as only two studies were included in the meta-analysis. Overall risk of bias across studies analysed was moderate to serious (eTable 11 in the Supplement). Key concerns were attributed to potential bias due to residual confounding and outcome measurement. Overall certainty in the evidence was very low (Table 3). No studies measured the association between the time since last dose of GLP-1 RA and pulmonary aspiration.

## **Discussion**

In this systematic review and meta-analysis, we assessed data from 25 observational studies involving 464,552 participants to evaluate the relationship between GLP-1 RA use and risk of perioperative aspiration among patients undergoing elective procedures. Our

findings indicate that patients using GLP-1 RAs prior to an elective procedure are at a higher risk of presenting with residual gastric contents compared to those not using GLP-1 RAs. Despite this, the available evidence does not indicate that preoperative GLP-1 RA use is associated with risk of perioperative aspiration, and the relationship between withholding GLP-1 RAs before surgery and aspiration risk remains unstudied. Pooled estimates from a small number of studies indicate that withholding at least one dose of their GLP-1 RA before surgery does not significantly lower the risk of presenting with residual gastric contents, when compared to maintaining a regular dosing schedule. However, the potential influence of residual confounding across included studies and imprecision in this estimate substantially weakens our certainty in these findings.

These findings may provide some degree of reassurance to both patients and clinicians about the risk of aspiration among patients using GLP-1 RAs prior to elective procedures. However, some caution is warranted, given low to very low certainty in the available evidence. High rates of residual gastric contents among these patients may be a cause for concern, independent of any assumed association with aspiration risk. Gastric residue may complicate procedures that require clear stomach visualization, such as gastroscopy, potentially leading to aborted procedures due to inadequate gastric clearance. Aborted procedures expose patients to unnecessary anesthetic risks while also adversely affecting the efficient of healthcare resources.<sup>42</sup> Consequently, these findings indicate that tailored guidance on the perioperative management of GLP-1 RAs may be warranted for procedures reliant on an empty stomach even in the absence of heightened aspiration risk.

Consensus-based guidance from the ASA currently recommends holding at least one GLP-1 RA dose prior to an elective procedure,<sup>16</sup> while other professional bodies have

refrained from endorsing similar recommendations.<sup>18-20</sup> This review identified no direct evidence to support the assumption that holding GLP-1 RA medications is associated with a lower risk of aspiration and there is very low certainty evidence that withholding at least one dose of GLP-1 RA prior to a procedure is not associated with a lower odd of residual gastric contents. Importantly, available studies did not examine the potential risks of withholding these medications, such as glycaemic instability or abrupt increases in blood pressure.<sup>43</sup> Given the absence of evidence relating to such risks and the small absolute risk of aspiration following appropriate fasting, it remains unclear if routinely withholding GLP-1 RA medications is warranted prior to elective procedures.

This review highlights the need for targeted research exploring the risks and benefits of strategies for managing GLP-1 RA medications prior to elective procedures. While several ongoing observational studies were identified in this review, it is unclear whether their findings will add to the current evidence in a way that alters clinical practice. Importantly, only one randomized controlled trial on the effect of withholding GLP-1 RAs on aspiration and increased residual gastric content risk was identified by our search of ongoing studies. Such trials are urgently needed to assess the efficacy and safety of holding these medications prior to surgery, and of alternative strategies such as using daily-dosed GLP-1 RAs as bridging therapies prior to surgery,<sup>44</sup> routinely using prokinetic agents,<sup>45</sup> or altering fasting protocols for patients using these medications.<sup>46</sup> A rapid update to this review will be warranted once data is available from randomized controlled trials, as such evidence will be critical to informing recommendations presented in future clinical practice guidelines.

## **Limitations**

The findings of this review should be interpreted within the context of several limitations. First, there was heterogeneity in how outcomes were described across the included studies. This included differences in measurement methods, such as using endoscopy versus gastric ultrasound to assess gastric contents, and differences in outcome definitions, such as distinguishing between pulmonary aspiration and aspiration pneumonitis. Second, the available evidence is drawn largely from populations undergoing upper endoscopies, a procedure that is unique insofar as it allows for intraoperative management to be altered following direct visualization of residual gastric contents. This may limit the applicability of our findings to patients undergoing most types of elective procedures. Third, an absence of studies with a pre-registered protocol raises concerns about potential selective analysis and reporting, though the findings appeared to be largely robust to publication bias. Fourth, none of the studies were judged to be a low risk of bias, which is reflected in the overall certainty of the evidence being low to very low. Finally, we excluded two potentially eligible studies that were not published in English.<sup>47, 48</sup> It is unclear if this exclusion is likely to have altered our findings.

## **Conclusion**

This systematic review and meta-analysis found that patients using GLP-1 RAs are at a heightened risk of presenting for surgery with residual gastric contents, though this does not necessarily indicate an increased risk of aspiration. The available evidence to support withholding GLP-1 RAs before surgery is derived from a small number of observational studies and is impacted by a high degree of uncertainty. Given the uncertainty of evidence and absence of randomized controlled trials, ongoing research is needed to evaluate the risks and benefits of different strategies for managing these medications during the perioperative period.



## **Acknowledgements**

### **Author contributions:**

JE and CS had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

### **Conflict of Interest Disclosures:**

PS reported a National Health and Medical Research Council (NHMRC) grant, paid to her institution, in the past 36 months; reported being a council member of the Australian and New Zealand Obesity Society (ANZOS) and a member of The Obesity Collective leadership group; and reported being a co-author on manuscripts with a medical writer provided by Novo Nordisk, Eli Lilly. CS reported receiving research support for investigator-initiated studies, paid to his institution, from Eli Lilly, St. Vincent's Hospital Research Foundation. MD reported receiving research support for investigator-initiated studies, paid to her institution, from Medical Research Future Fund, NHMRC, Eli Lilly, Victorian Orthopaedic Foundation, Australian Orthopaedic Association Research Foundation, HCF Foundation, University of Melbourne, St. Vincent's Hospital Research Foundation, and Arthritis & Osteoporosis Western Australia; reported receiving payment for provision of advice on guideline development for the Royal Australian College of General Practitioners; reported receiving a sitting fee as a member of the Osteoarthritis Clinical Research Group Data & Safety Monitoring Board; and reported being a Board Director of the Australian Orthopaedic Association Research Foundation. MH reported receiving honoraria for lecture to Pillars of Dermatology Practice Symposium; and being a Chairperson for the HOPE fund. PC reported receiving research support for investigator-initiated studies from Medacta, Eli Lilly, Medibank Private, HCF foundation, National Health, Medical Research Foundation, and Medical Research Future Fund; received

royalty fees from Kluwer; received consultancy fees from DePuy, Surgeon advisory board, Stryker Corporation, Johnson and Johnson, and Medacta; reported being on the Editorial Board for EFORT Reviews and Journal of Clinical Medicine, and reported being an international corresponding editor for JAAOS International. No other disclosures were reported.

**Funding/Support:** JE was supported to conduct this work by an Australian Government Research Training Program (RTP) Scholarship. No other funding or support was received.

## References

1. Jensterle M, Rizzo M, Haluzík M, Janež A. Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. *Advances in therapy*. 2022;39(6):2452-2467.
2. Aldawsari M, Almadani FA, Almuhammad N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of randomized controlled trials. *Diabetes, Metabolic Syndrome and Obesity*. 2023:575-595.
3. Jensterle M, Ferjan S, Lezaic L, Socan A, Goricar K, Zaletel K, Janez A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. *Diabetes, Obesity and Metabolism*. 2023;25(4):975-984.
4. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. *Obesity*. 2022;30(8):1608-1620.
5. Beam W, Hunter Guevara L. Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients undergoing anesthesia. *Anesthesia Patient Safety Foundation (APSF Newsletter)*. 2023;38(2):69-71.
6. Girón-Arango L, Perlas A. Point-of-Care Gastric Ultrasound to Identify a Full Stomach on a Diabetic Patient Taking a Glucagon-Like Peptide 1 Receptor Agonist. *A&A Practice*. 2024;18(2):e01751.
7. Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2023;70(8):1397-1400.
8. Kittner SL, Talbott AL, Vishneski SR, Narbaiza J, Shields JS. Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases. *JBJS Case Connector*. 2023;13(4):e23.
9. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2023;70(8):1394-1396.
10. Preda V, Khoo SS-Y, Preda T, Lord RV. Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery. *BJS open*. 2023;7(1):zrac169.
11. Queiroz VNF, Falsarella PM, Chaves RCdF, Takaoka F, Socolowski LR, Garcia RG. Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence. *einstein (São Paulo)*. 2023;21:eRC0628.
12. Raven LM, Stoita A, Feller RB, Brown C, Greenfield JR. Delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists. *The American Journal of Medicine*. 2023;136(12):e233-e234.
13. Weber M, Siddarthan I, Mack PF. Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss. *BJA*. 2023;131(2):e37-e39.
14. Wilson PR, Bridges KH, Wilson SH. Particulate gastric contents in patients prescribed glucagon-like peptide 1 receptor agonists after appropriate perioperative fasting: a report of 2 cases. *A&A Practice*. 2023;17(8):e01712.

15. ANZCA. Surgery warning on use of popular weight loss drugs. <https://www.anzca.edu.au/resources/media-releases/2023-media-releases/gastric-emptying-mr.pdf>. Accessed June 30, 2024.
16. ASA. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-421-on-preoperative>. Accessed June 30, 2024.
17. AGA. No data to support stopping GLP-1 agonists prior to elective endoscopy 2023. <https://gastro.org/news/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy/>. Accessed June 30, 2024.
18. ANZCA. Clinical Practice Recommendation On Perioperative Use Of GLP-1/GIP Receptor Agonists. <https://www.anzca.edu.au/news/glp-1-gip-receptor-agonists-clinical-practice-guid>. Accessed on July 05, 2024.
19. Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. *Clinical Gastroenterology and Hepatology*. 2024;22(4):705-707.
20. CPOC. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. [https://cpoc.org.uk/sites/cpoc/files/documents/2021-03/CPOC-Diabetes-434-Guideline2021\\_0.pdf](https://cpoc.org.uk/sites/cpoc/files/documents/2021-03/CPOC-Diabetes-434-Guideline2021_0.pdf). Accessed June 20, 2024.
21. Facciorusso A, Ramai D, Dhar J, et al. Effects of Glucagon-Like Peptide-1 receptor agonists on upper gastrointestinal endoscopy: A meta-analysis. *Clinical Gastroenterology and Hepatology*. 2024.
22. Singh S, Rahman SH, Khan N, et al. Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: A systematic review & meta-analysis. *Gastrointestinal Endoscopy*. 2024.
23. do Nascimento TS, Pereira RO, Maia E, et al. The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis. *Perioperative Medicine*. 2024;13(1):78.
24. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *International journal of surgery*. 2021;88:105906.
25. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000;283(15):2008-2012.
26. Haddaway NR, Grainger MJ, Gray CT. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching. Zenodo, doi:10.5281/zenodo.4533747
27. Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration\*. *Anesthesiology*. 2017;126(3):376-93.
28. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at [www.covidence.org](http://www.covidence.org).


29. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023). Cochrane, 2023. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
30. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in medicine*. 2004;23(9):1351-1375.
31. Viswanathan M, Patnode CD, Berkman ND, et al. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. *Journal of clinical epidemiology*. 2018;97:26-34.
32. Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. *BMJ*. 2019;364:k4597.
33. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. *Annals of internal medicine*. 2013;158(4):280-286.
34. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.
35. Langan D, Higgins JP, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Research synthesis methods*. 2019;10(1):83-98.
36. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. *Statistics in medicine*. 1996;15(6):619-629.
37. Mathur MB. Assessing robustness to worst case publication bias using a simple subset meta-analysis. *BMJ*. 2024;384.
38. Foroutan F, Guyatt G, Zuk V, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *Journal of clinical epidemiology*. 2020;121:62-70.
39. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *BMJ Ment Health*. 2019;22(4):153-160.
40. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical Software*. 2010;36(3):1-48.
41. Hussein H, Nevill CR, Meffen A, Abrams KR, Bujkiewicz S, Sutton AJ, Gray LJ. Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological development. *BMC public health*. 2022;22(1):1827.
42. Hori Y, Nakayama A, Sakamoto A. Surgery cancellations after entering the operating room. *JA Clinical Reports*. 2016;2:1-4.
43. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*. 2024;331(1):38-48.
44. US Food and Drug Administration. Saxenda prescribing information. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321>. Accessed August 15, 2024.
45. Vijayvargiya P, Camilleri M, Chedid V, Mandawat A, Erwin PJ, Murad MH. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. *Gastroenterology*. 2019;156(6):1650-1660.

46. Faigel DO, Eisen GM, Baron TH, Dominitz JA, Goldstein JL, Hirota WK, et al. Preparation of patients for GI endoscopy. *Gastrointestinal endoscopy*. 2003;57(4):446-450.
47. Benhamou D, Catargi B, Cheisson G, Cosson E, Ichai C, Jacqueminet S, et al. Agonistes du récepteur du GLP1 (AR-GLP1) et dérivés, vidange gastrique et anesthésie. *Anesthésie & Réanimation*. 2023;9(5):510-511.
48. Kahl S. Hyperglykämie verstärkt die magenentleerungshemmende Wirkung von exogenem GLP-1. *Der Diabetologe*. 2015;11(5):413-414.
49. Abu-Freha N, Levi Z, Nevo-Shor A, et al. The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy. *Diabetes Research and Clinical Practice*. 2024:111900.
50. Alkabbani W, Suissa K, Gu KD, et al. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. *BMJ*. 2024;387:e080340.
51. Amini RAS, Ismail A-LS, Al-Aqrabawi M, et al. Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists. *Cureus*. 2024;16(8).
52. Barlowe TS, Anderson C, Sandler RS, et al. Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes. *Clinical Gastroenterology and Hepatology*. 2024.
53. Bi D, Choi C, League J, Camilleri M, Prichard DO. Food residue during esophagogastroduodenoscopy is commonly encountered and is not pathognomonic of delayed gastric emptying. *Digestive diseases and sciences*. 2021;66:3951-9.
54. Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty. *Journal of Arthroplasty*. 2024.
55. Chapman MB, Norwood DA, Price C, et al. Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD. *Gastrointestinal Endoscopy*. 2024.
56. Elimihle TA, Mangrola AM, Oshomiji O, et al. Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study. *Cureus*. 2024;16(9):e69152.
57. Garza K, Aminpour E, Shah J, Mehta B, Early D, Gyawali CP, Kushnir V. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study. *The American journal of gastroenterology*. 2024;119(6):1081-8.
58. Klonoff DC, Kim SH, Galindo RJ, et al. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists. *Diabetes, Obesity and Metabolism*. 2024.
59. Kobori T, Onishi Y, Yoshida Y, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. *Journal of Diabetes Investigation*. 2023;14(6):767-73.
60. Korlipara H, Chua J, Buckholz A, et al. Semaglutide is an Independent Predictor of Retained Solid Gastric Contents, but Same Day Colonoscopy Mitigates Effect. *Techniques and Innovations in Gastrointestinal Endoscopy*. 2024.



61. Nadeem D, Taye M, Still MD, et al. Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy in Diabetic and Non-Diabetic Patients. *Gastrointestinal Endoscopy*. 2024.
62. Nasser J, Hosseini A, Barlow G, Gianchandani R, Rezaie A, Pimentel M, Mathur R. Food Retention at Endoscopy Among Adults Using Glucagon-Like Peptide-1 Receptor Agonists. *JAMA network open*. 2024;7(10):e2436783.
63. Peng C-Y, Chang Y-C, Gong C, et al. Association between Glucagon-like Peptide-1 Receptor Agonists and Aspiration Pneumonia during Endoscopic Procedures. *Anesthesiology*. 2024;141(5):1009-1012.
64. Phan J, Chang P, Issa D, et al. Glucagon-Like Peptide Receptor Agonists Use before Endoscopy Is Associated with Low Retained Gastric Contents: A Multicenter Cross-Sectional Analysis. *American Journal of Gastroenterology*. 2024.
65. Queiroz VNF, Falsarella PM, Chaves RCDF, et al. Evaluation of gastric content in fasting patient during semaglutide use: an observational study. *Surgery for Obesity and Related Diseases*. 2024.
66. Robalino Gonzaga E, Farooq A, et al. Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center. *Journal of Clinical Medicine*. 2024;13(18):5403.
67. Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S, Nwokolo OO. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. *JAMA surgery*. 2024.
68. Sherwin M, Hamburger J, Katz D, DeMaria Jr S. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2023;70(8):1300-1306.
69. Silveira SQ, da Silva LM, Abib AdCV, et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. *Journal of Clinical Anesthesia*. 2023;87:111091.
70. Stark JE, Cole JL, Ghazarian RN, Klass MJ. Impact of glucagon-like Peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD). *Annals of Pharmacotherapy*. 2022;56(8):922-926.
71. Welk B, McClure JA, Carter B, Clarke C, Dubois L, Clemens KK. No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery. *Diabetes, Obesity and Metabolism*. 2024.
72. Wu F, Smith MR, Mueller AL, Klapman SA, et al. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2024:1-9.
73. Yeo YH, Gaddam S, Ng WH, et al. Increased Risk of Aspiration Pneumonia Associated With Endoscopic Procedures Among Patients With Glucagon-like Peptide 1 Receptor Agonist Use. *Gastroenterology*. 2024.
74. Schünemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)*. Cochrane, 2023. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).


**Figure 1. PRISMA diagram**



Abbreviations: GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonist



**Figure 2a. Forest plot pulmonary aspiration**




Heterogeneity:  $\chi^2 = 5.66$  ( $P = .69$ ),  $I^2 = 0\%$

Test for overall effect:  $z = 0.48$  ( $P = .63$ )

Random-effects model method: restricted maximum likelihood heterogeneity variance estimator. The dark blue boxes represent individual study odds ratio, and the size of the boxes are proportional to study weight in the meta-analysis; the whiskers represent the confidence intervals; light blue diamond represents the overall pooled odds ratio and 95% CI; the dotted vertical line indicates the pooled OR. Event rates were not reported by Welk 2024. Abbreviations: GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonist.

**Figure 2b. Forest plot residual gastric contents**

Source	GLP-1 RA Non-users		GLP-1 RA Users		Adjusted	OR	95% CI	Weight
	No. of events	No. of patients	No. of events	No. of patients				
Abu-Freha 2024	2372	119208	93	1671	Yes	2.13	[1.70; 2.68]	17.3%
Bi 2021	.	.	.	.	Yes	5.30	[0.52; 54.15]	1.8%
Chapman 2024	4	84	11	84	Yes	4.62	[1.21; 17.60]	4.5%
Elimihele 2024	126	3381	3	34	No	2.50	[0.75; 8.31]	5.3%
Garza 2024	12	306	43	306	Yes	4.35	[2.21; 8.57]	10.4%
Kobori 2023	1	205	11	205	Yes	11.57	[1.48; 90.44]	2.2%
Korlipara 2024	.	610	.	602	Yes	4.74	[2.40; 9.36]	10.3%
Nadeem 2024	788	34261	125	922	Yes	4.08	[3.25; 5.12]	17.3%
Nasser 2024	0	139	4	70	Yes	18.88	[1.00; 355.81]	1.2%
Queiroz 2024	1	15	11	15	No	38.50	[3.75; 395.41]	1.8%
Robalino Gonzaga 2024	15	973	10	73	Yes	9.19	[2.74; 30.88]	5.2%
Sen 2024	12	62	35	62	Yes	4.16	[1.60; 10.82]	7.2%
Sherwin 2023	1	10	9	10	No	81.00	[4.36; 1504.46]	1.2%
Silveira 2023	19	371	8	33	Yes	7.65	[2.64; 22.15]	6.3%
Stark 2022	2	118	4	59	Yes	4.22	[0.87; 20.40]	3.5%
Wu 2024	5	102	17	90	Yes	6.30	[1.73; 22.88]	4.8%
Total						4.57	[3.30; 6.33]	100.0%




Heterogeneity:  $\chi^2_{15} = 37.90$  ( $P < .001$ ),  $I^2 = 60\%$

Test for overall effect:  $z = 9.16$  ( $P < .001$ )

Random-effects model method: restricted maximum likelihood heterogeneity variance estimator. The dark blue boxes represent individual study odds ratio, and the size of the boxes are proportional to study weight in the meta-analysis; the whiskers represent the confidence intervals; light blue diamond represents the overall pooled odds ratio and 95% CI; the dotted vertical line indicates the pooled OR. Event rates were not reported by Bi 2021 and Korlipara 2024. Abbreviations: GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonist.

**Figure 2c. Forest plot time since last dose**

Source	GLP-1 RA not held		GLP-1 RA held		Adjusted	OR	95% CI	Weight
	No. of events	No. of patients	No. of events	No. of patients				
Sen 2024	30	55	5	7	Yes	2.15	[0.29; 15.86]	35.6%
Phan 2024	52	409	18	406	Yes	0.35	[0.19; 0.64]	64.4%
Total						0.67	[0.12; 3.67]	100.0%



Heterogeneity:  $\chi^2_1 = 2.91$  ( $P = .09$ ),  $I^2 = 66\%$   
 Test for overall effect:  $z = -0.46$  ( $P = .64$ )

Random-effects model method: restricted maximum likelihood heterogeneity variance estimator. The dark blue boxes represent individual study odds ratio, and the size of the boxes are proportional to study weight in the meta-analysis; the whiskers represent the confidence intervals; light blue diamond represents the overall pooled odds ratio and 95% CI; the dotted vertical line indicates the pooled OR. Abbreviations: GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonist.

**Table 1. Characteristics of included studies**

Study	Country	Data collection	Study Design	Sample Size, No.	Female, No. (%)	Diabetes, No. (%)	Population	Exposure Arm	Outcome measured
Abu-Freha 2024 <sup>49</sup>	Israel	Retrospective	Cohort / Cross-sectional	120879	70444 (58%)	11293 (9%)	EGD	Any GLP-1 RA	RGC
Alkabbani 2024 <sup>50</sup>	United States	Retrospective	Cohort / Cross-sectional	43354	27609 (64%)	43354 (100%)	EGD	Any GLP-1 RA	PA
Amini 2024 <sup>51</sup>	United States	Retrospective	Cohort / Cross-sectional	118646	53796 (45%)	103070 (87%)	EGD	Any GLP-1 RA	PA
Barlowe 2024 <sup>52</sup>	United States	Retrospective	Cohort / Cross-sectional	29526	16466 (56%)	29526 (100%)	EGD	Any GLP-1 RA	PA
Bi 2021 <sup>53</sup>	United States	Retrospective	Case-control	249	NR	NR	EGD	Any GLP-1 RA	RGC
Buddhiraju 2024 <sup>54</sup>	United States	Retrospective	Cohort / Cross-sectional	4190	2548 (61%)	2872 (69%)	TKA	Any GLP-1 RA	PA
Chapman 2024 <sup>55</sup>	United States	Retrospective	Cohort / Cross-sectional	168	118 (70%)	144 (86%)	EGD	Any GLP-1 RA	RGC
Elimihele 2024 <sup>56</sup>	United States	Retrospective	Cohort / Cross-sectional	3415	1609 (47%)	NR	EGD and/or colonoscopy	Any GLP-1 RA	RGC
Garza 2024 <sup>57</sup>	United States	Retrospective	Cohort / Cross-sectional	612	303 (50%)	537 (88%)	EGD	Any GLP-1 RA	RGC
Klonoff 2024 <sup>58</sup>	United States	Retrospective	Cohort / Cross-sectional	2592	1677 (65%)	2592 (100%)	Mixed surgical procedures	Any GLP-1 RA	PA
Kobori 2023 <sup>59</sup>	Japan	Retrospective	Cohort / Cross-sectional	410	93 (23%)	410 (100%)	EGD	Any GLP-1 RA	RGC
Korlipara 2024 <sup>60</sup>	United States	Retrospective	Cohort / Cross-sectional	1212	845 (70%)	555 (46%)	EGD	Semaglutide only	RGC
Nadeem 2024 <sup>61</sup>	United States	Retrospective	Cohort / Cross-sectional	35183	20,749 (59%)	6163 (18%)	EGD	Any GLP-1 RA	PA; RGC
Nasser 2024 <sup>62</sup>	United States	Retrospective	Cohort / Cross-sectional	209	108 (52%)	100 (48%)	EGD and/or colonoscopy	Any GLP-1 RA	RGC

Abbreviations: EGD, esophagogastroduodenoscopy; GLP-1 RA, glucagon-like peptide-1 receptor agonist; NR, not reported; PA, pulmonary aspiration; RGC, residual gastric contents; TKA, total knee arthroplasty.

**Table 1. Characteristics of included studies (continued)**

Study	Country	Data collection	Study Design	Sample Size, No.	Female, No. (%)	Diabetes, No. (%)	Population	Exposure Arm	Outcome measured
Peng 2024 <sup>63</sup>	United States	Retrospective	Cohort / Cross-sectional	51378	31529 (61%)	39376 (77%)	Mixed endoscopy procedures	Any GLP-1 RA	PA
Phan 2024 <sup>64</sup>	United States	Retrospective	Cohort / Cross-sectional	815	470 (58%)	672 (82%)	EGD	Any GLP-1 RA	RGC
Queiroz 2024 <sup>65</sup>	Brazil	Prospective	Cohort / Cross-sectional	30	17 (57%)	NR	Healthy volunteers	Semaglutide only	RGC
Robalino Gonzaga 2024 <sup>66</sup>	United States	Retrospective	Cohort / Cross-sectional	1046	675 (65%)	184 (17.6)	EGD	Any GLP-1 RA	RGC
Sen 2024 <sup>67</sup>	United States	Prospective	Cohort / Cross-sectional	124	75 (60%)	59 (48%)	Mixed surgical procedures	Long-acting GLP-1 RA only	RGC
Sherwin 2023 <sup>68</sup>	United States	Prospective	Cohort / Cross-sectional	20	8 (40%)	1 (5%)	Healthy volunteers	Semaglutide only	RGC
Silveira 2023 <sup>69</sup>	Brazil	Retrospective	Cohort / Cross-sectional	404	196 (49%)	38 (9%)	EGD	Semaglutide only	PA; RGC
Stark 2022 <sup>70</sup>	United States	Retrospective	Cohort / Cross-sectional	177	17 (10%)	173 (98%)	EGD	Any GLP-1 RA	RGC
Welk 2024 <sup>71</sup>	Canada	Retrospective	Cohort / Cross-sectional	17905	7047 (39%)	17905 (100%)	Mixed surgical procedures	Semaglutide only	PA
Wu 2024 <sup>72</sup>	United States	Retrospective	Cohort / Cross-sectional	192	110 (57%)	87 (45%)	EGD	Any GLP-1 RA	PA; RGC
Yeo 2024 <sup>73</sup>	United States	Retrospective	Cohort / Cross-sectional	31816	17753 (56%)	28823 (91%)	EGD and/or colonoscopy	Any GLP-1 RA	PA

Abbreviations: EGD, esophagogastroduodenoscopy; GLP-1 RA, glucagon-like peptide-1 receptor agonist; NR, not reported; PA, pulmonary aspiration; RGC, residual gastric contents.

**Table 2. Characteristics of included studies by outcome**

	<b>Pulmonary Aspiration</b>	<b>Residual gastric content</b>
Number of included studies	11	17
Number of participants	335186	165145
Sample size, Median (IQR)	29526 (3391 - 39268)	404 (177 - 1046)
<b>Publication year, No. (%)</b>		
2021	0	1 (6 %)
2022	0	1 (6 %)
2023	1 (9 %)	3 (18 %)
2024	10 (91 %)	12 (71 %)
<b>Country, No. (%)</b>		
Brazil	1 (9 %)	2 (12 %)
Canada	1 (9 %)	0
Israel	0	1 (6 %)
Japan	0	1 (6 %)
United States	9 (82 %)	13 (76 %)
<b>Population, No. (%)</b>		
EGD	6 (55 %)	12 (71 %)
EGD and/or colonoscopy	1 (9 %)	2 (12 %)
Mixed endoscopy procedures	1 (9 %)	0
Mixed surgical procedures	2 (18 %)	1 (6 %)
TKA	1 (9 %)	0
Healthy volunteers	0	2 (12 %)
<b>Data collection, No. (%)</b>		
Prospective	0	3 (18 %)
Retrospective	11 (100 %)	14 (82 %)
<b>Exposure type, No. (%)</b>		
Any GLP-1 RA	9 (82 %)	12 (71 %)
Long-acting GLP-1 RA only	0	1 (6 %)
Semaglutide only	2 (18 %)	4 (24 %)
<b>Diabetes only sample, No. (%)</b>		
Yes	4 (36 %)	2 (12 %)
No	7 (64 %)	15 (88 %)
<b>Assessed time since last dose, No. (%)</b>		
Yes	0	3 (18 %)
No	11 (100 %)	14 (82 %)

Percentages may not sum to exactly 100 due to rounding.

Abbreviations: EGD, esophagogastroduodenoscopy; GLP-1 RA, glucagon-like peptide-1 receptor agonist; TKA, total knee arthroplasty.

**Table 3. Summary of findings and GRADE assessment**

Outcome	No. of patients (studies)	Event rate control	Event rate exposure	Relative effects (95% CI)	Absolute Risk difference (95%CI)	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Large effects	Certainty of Evidence
Pulmonary aspiration <sup>a</sup>	184724 (9)	0.20% (218/110830)	0.34% (253/73894)	OR 1.04 (0.87 to 1.25)	1 more per 10,000 (2 fewer to 5 more)	Serious <sup>f</sup>	Not serious	Serious <sup>k</sup>	Not serious	Not serious	No upgrade	Low
Residual gastric contents <sup>a</sup>	164330 (16) <sup>c</sup>	2.1% (3358/159845)	9.1% (384/4236)	OR 4.57 (3.30 to 6.33)	68 more per 1,000 (44 more to 101 more)	Very serious <sup>g</sup>	Serious <sup>i</sup>	Serious <sup>l</sup>	Not serious	Not serious	Upgrade <sup>o</sup>	Very Low
Time since last dose <sup>b</sup>	877 (2)	17.7% (82/464) <sup>d</sup>	5.6% (23/413) <sup>e</sup>	OR 0.67 (0.12 to 3.67)	5 fewer per 100 (15 fewer to 26 more)	Very serious <sup>h</sup>	Serious <sup>j</sup>	Serious <sup>m</sup>	Very serious <sup>n</sup>	Not serious	No upgrade	Very Low

Not serious indicates that no reason was found, or the reason was not important enough to warrant downgrading the evidence; Serious indicates that the evidence is downgraded by one level; Very serious indicates that the evidence is downgraded by two levels; Upgrade indicates that the certainty of the evidence is increased by one level.

<sup>a</sup> In line with GRADE recommendations for assessment of evidence about prognostic factors, we started with a high certainty in the evidence.<sup>38</sup>

<sup>b</sup> In line with GRADE recommendations for outcomes assessed with the ROBINS-I tool, we started with high certainty of evidence.<sup>74</sup>

<sup>c</sup> One study did not report event rates for patients using GLP-1 RAs, therefore total number of patients is greater than the sum of control and exposure groups

<sup>d</sup> Control group involves patient who did not hold their GLP-1 RA prior to procedure

<sup>e</sup> Exposure group involves patients who held their GLP-1 RA for at least one dose prior to procedure

<sup>f</sup> Overall bias was moderate or high across included studies. Studies at high risk of bias did not meaningfully impact the pooled estimate. Concerns with incomplete or missing adjustment of confounders, potential selection bias, and inadequate details regarding outcome measurement.

<sup>g</sup> Overall bias was predominantly high across included studies. Concerns with incomplete or missing adjustment of confounders, potential selection bias, and inadequate details regarding outcome measurement.

<sup>h</sup> Overall bias was moderate to serious across included studies. Concerns with potential confounding and inadequate details regarding outcome measurement.

<sup>i</sup> Downgraded because of moderate to substantial heterogeneity (I<sup>2</sup>=60%).

<sup>j</sup> Downgraded because of substantial heterogeneity (I<sup>2</sup>=66%).

<sup>k</sup> Downgraded because 6/9 limited to endoscopic procedures and 4/9 limited to patients with diabetes.

<sup>l</sup> Downgraded because 13/16 limited to endoscopic procedures.

<sup>m</sup> Limited number of studies. Half limited to upper endoscopy procedures.

<sup>n</sup> Downloaded because of very wide confidence intervals.

<sup>o</sup> Certainty of evidence is increased by one level because the relative point estimate and confidence intervals are >2.